Daily Newsletter

23 November 2023

Daily Newsletter

23 November 2023

Entrada Therapeutics concludes dosing in DMD therapy trial

The company plans to reveal data from the trial in the second half of next year.

RanjithKumar Dharma November 23 2023

Entrada Therapeutics has concluded the first and second cohorts dosing for the ENTR-601-44-101 Phase I clinical study of its investigational therapy ENTR-601-44 to treat Duchenne muscular dystrophy (DMD).

DMD is a serious form of muscular dystrophy that mainly impacts boys. Weakness in the muscles typically starts around the age of four and progresses rapidly.

ENTR-601-44 is an Endosomal Escape Vehicle (EEV)-conjugated phosphorodiamidate morpholino oligomer (PMO).

ENTR-601-44-101 is a single ascending dose and double-blind study, which is anticipated to enrol around 40 subjects.

Assessing the tolerability and safety of a single ENTR-601-44 dose in healthy male volunteers is the primary objective of the Phase I study.

Furthermore, the trial will assess pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.

The company intends to reveal data from this trial in the second half of next year.

Entrada Therapeutics president and CEO Dipal Doshi said: “Our strategy has always been to run a single Phase I clinical trial for ENTR-601-44 and, notably, that trial is progressing in the UK.

“We are pleased to have completed dosing of the first and second cohorts of participants. In parallel with the Phase I clinical trial, we continue to plan for the global development of ENTR-601-44 which will include clinical trials in patients with Duchenne who are exon 44 skipping amenable.”

Entrada received prior notification from the US Food and Drug Administration (FDA) about the Phase I clinical trial of ENTR-601-44 being placed on hold.

Even after providing more details to the FDA, the company was informed that the agency decided not to remove the clinical hold.

The information submitted backed the start of the Phase I study in the UK in September.

During that month, Entrada dosed the first subject in the trial to assess ENTR-601-44.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close